BioSpace News Archive

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM), a biopharmaceutical company focused on the development and commercialization of therapeutics for the treatment of rare genetic disorders of obesity, today announced the launch of a new non-interventional patient registry, called Tracing the Effect of the MC4R Pathway in Obesity (TEMPO).

Lars Holmqvist has been appointed as Senior Advisor to Biovica. He will contribute to Biovica’s commercialization strategy and will be very helpful as strategic support for future marketing in the US and Europe.

TransThera Biosciences Co. Ltd, announced today that the company received FDA IND application approval for TT-00420, a novel small molecule investigational drug targeting Triple-Negative Breast Cancer (TNBC).

CEL-SCI Corporation is advising the holders of its publicly traded warrants (NYSE American: CVM WS) that the warrants will expire and not be exercisable after 5:00 p.m., New York City time, on October 11, 2018.

Life Sciences Ontario (LSO) applauds the Federal Government’s recommendations in its Health and Biosciences Economic Strategy Tables, released earlier this wee

Walgreens Boots Alliance, Inc. (Nasdaq: WBA) announced today that the company has reached an agreement with the Securities and Exchange Commission (SEC) to fully resolve an investigation into forward-looking financial goals and related disclosures by Walgreen Co. (Walgreens).

BioConnect is pleased to announce that Julia Webb, former VP of Sales and Marketing at VoiceVault, will be joining BioConnect as Vice President, Alliances and reporting to CEO and Chairman, Rob Douglas.

Agreement creates academic health system focused on patient-centered care, innovation and clinical excellence

Apotheker Group, Search and Advisory, an Executive Search & Advisory firm specializing in the life sciences industry, is hosting an invite-only event on Thursday, October 4th, 2018 at the Dream Downtown Hotel in Manhattan, NY to celebrate its recent launch as well as the newly appointed ACMA Board of Governors.

A Lupus Foundation of America-led delegation, including several world-renowned lupus experts and senior leaders from the Foundation, met with more than a dozen top decision makers at the Food and Drug Administration (FDA) to present recommendations for improving lupus clinical trial design and to discuss actionable steps toward advancing these solutions.